Document Detail


Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.
MedLine Citation:
PMID:  11874491     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recent clinical studies have shown the promise of bcl-2 antisense therapy in patients with melanoma. To further demonstrate the importance of bcl-2 and validate the related antiapoptotic protein bcl-xL as targets for antisense therapy in melanoma, their implication as survival factors in melanoma cells of different clinical stages as well as in normal melanocytes was investigated. Primary cell cultures derived from 17 melanomas, the cell line A375, and normal melanocytes from healthy donors were treated with antisense oligonucleotides targeting either the bcl-xL mRNA or the bcl-2 and the bcl-xL mRNAs simultaneously. Bcl-2 and bcl-xL expression in cells was analyzed by real-time polymerase chain reaction and Western blotting. Cell viability was assessed in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and apoptosis assays. Bcl-2 expression was low in melanoma cells of stages I, II, and III, hardly detectable in A375 cells, but high in normal melanocytes. Bcl-xL expression was high in all cell types tested. As shown in A375 cells and the stage III melanoma cells 0513, both the bcl-xL monospecific oligonucleotide 4259 and the bcl-2/bcl-xL bispecific oligonucleotide 4625 effectively reduced tumor cell viability by induction of apoptosis with IC50 values ranging from 200 to 350 nM. Oligonucleotide 4625 proved to be superior to 4259, as it significantly reduced the viability of cells from all melanoma stages. Both oligonucleotides reduced also the viability of normal melanocytes. Our data suggest that bcl-2 and bcl-xL are promising targets for antisense therapy of melanoma, and that the simultaneous downregulation of their expression may provide additional clinical benefit.
Authors:
Robert A Olie; Christoph Hafner; Renzo Küttel; Brigitte Sigrist; Jörg Willers; Reinhard Dummer; Jonathan Hall; Rolf A Stahel; Uwe Zangemeister-Wittke
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of investigative dermatology     Volume:  118     ISSN:  0022-202X     ISO Abbreviation:  J. Invest. Dermatol.     Publication Date:  2002 Mar 
Date Detail:
Created Date:  2002-03-04     Completed Date:  2002-04-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0426720     Medline TA:  J Invest Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  505-12     Citation Subset:  IM    
Affiliation:
Division of Oncology, Department of Internal Medicine, University Hospital Zürich, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Apoptosis* / physiology
Cell Division / physiology
Cell Survival / physiology
Down-Regulation / physiology
Gene Expression / drug effects
Genes, bcl-2 / genetics*
Humans
Melanocytes / metabolism
Melanoma / pathology,  physiopathology*
Neoplasm Staging
Oligonucleotides, Antisense / pharmacology*
Proto-Oncogene Proteins c-bcl-2 / genetics*,  metabolism
Reference Values
Tumor Cells, Cultured
bcl-X Protein
Chemical
Reg. No./Substance:
0/BCL2L1 protein, human; 0/Oligonucleotides, Antisense; 0/Proto-Oncogene Proteins c-bcl-2; 0/bcl-X Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evolution of melanocytic nevi on the faces and necks of adolescents: a 4 y longitudinal study.
Next Document:  Oxidative stress-independent depletion of epidermal vitamin A by UVA.